ARISE (Aggressive Reduction of Inflammation Stops Events)

To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events.

To assess the safety and efficacy of AGI-1067, as compared to placebo, in the treatment of vascular inflammation and atherosclerosis by assessing the reduction in cardiovascular events. Condition: – Atherosclerosis- Coronary Artery Disease- Myocardial Infarction- Unstable Angina Study Type: InterventionalStudy Design: Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study Official Title: Reduction of Vascular Inflammation and Coronary Atherosclerosis with AGI-1067, a V-Protectant, Reduces Cardiovascular Events in Patients With Coronary Artery Disease Eligibility Ages Eligible for Study: 55 Years and above, Genders Eligible for Study: Both Criteria IRB-approved informed written consent must be provided by all subjects prior to screening and study entry.Subjects with a recent diagnosis of coronary artery disease. Male or female aged 55 years or older with additional risk factors. Females must be non-lactating and not of child bearing potential (post-menopausal or surgically sterilized) or must use a reliable method of birth control considered suitable by the Investigator. [1] AtheroGenics